Innovative Therapies in Hodgkin Lymphoma Management
Summary
Recent advances in Hodgkin lymphoma management have shifted from uniform, dose‐intense chemotherapy and radiotherapy towards tailored, biology-driven approaches that aim to maximise cure rates while reducing acute and late toxicities. Antibody-drug conjugates targeting CD30 have revolutionised salvage and consolidation treatment, delivering cytotoxic payloads directly to Hodgkin and Reed-Sternberg cells. Immune checkpoint inhibitors that block the PD-1/PD-L1 axis have demonstrated durable remissions in relapsed or refractory disease, transforming the therapeutic landscape for patients who have exhausted conventional options. PET-adapted strategies enable early response assessment and permit de-escalation or intensification of therapy, optimising the balance between efficacy and long-term risk. Emerging combinations of brentuximab vedotin with chemotherapy backbones, novel small‐molecule inhibitors of JAK/STAT signalling and chimeric antigen receptor T cells are under evaluation, underscoring an era in which molecularly informed, patient-specific regimens are becoming standard.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Innovative Therapies in Hodgkin Lymphoma Management publication trend
The graph below shows the total number of articles in innovative therapies in hodgkin lymphoma management across all publications each year (not limited to Nature Index journals).
Technical terms
Antibody-drug conjugate: A molecule linking a monoclonal antibody to a cytotoxic agent for targeted delivery.
Checkpoint inhibitor: A monoclonal antibody that blocks inhibitory immune receptors, restoring T-cell activity against tumour cells.
Positron emission tomography (PET): An imaging modality assessing metabolic activity to guide response-adapted therapy.
Progression-free survival (PFS): The interval during which a patient’s disease does not worsen under treatment.
References
- Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. The Lancet (2024).
- Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Signal Transduction and Targeted Therapy (2023).
- Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia (2019).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.